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A 65year old patient is admitted to the ICU 5 days after right upper lobectomy 
with oliguria (urine output over the past 24h 0.17ml/kg/h =AKI stage 3) and 
relative hypotension. Serum creatinine has increased from a baseline of 1.36 
mg/dL (eGFR 53) to 3.78 mg/dL (AKI stage 2). He has an ileus with vomiting. 
Antibiotics were commenced 24h earlier because of rising CRP. Postoperative 
medications included ACE-inhibition and NSAID’s. Following ICU admission 
further fluid resuscitation is commenced as is norepinephrine 
(0.15microg/kg/min) and the antibiotic spectrum is broadened empirically as the 
CRP has increased further (505mg/L). Next morning his creatinine has increased 
to 4.53mg/dl (AKI stage 3), urine output has decreased to 0.1ml/kg/h over the past 
12h resulting in a positive fluid balance of 3300ml. Arterial blood gas analysis 
reveals a pH of 7.39. PaO2 is 87mmHg, bicarbonate 25meq/L, K+ 3.9meq/L and 
urea 128mg/dL He is breathing spontaneously on 2LO2 with a respiratory rate of 
20 breaths/min and chest X-ray shows bilateral basal infiltrates and a limited 
hydropneumothorax on the lobectomy side.  
 
Does this patient need RRT?  Which factors may guide this decision? 
1. Does this patient have an absolute indication for commencing RRT 
immediately?  Generally accepted “classical” indications for urgent RRT 
include potentially fatal changes in fluid, electrolyte and acid-base balance 
and severe azotemia with complications (uremic encephalopathy, 
pericarditis,….) 1 but agreement on the thresholds for treatment is 
lacking 2. None of these indications appear to apply to our patient.  
2. Should we wait until the development of classical indications or will 
commencing RRT earlier improve our patient outcome? Over the past 15 
years three small (underpowered) randomized trials 3-5 have addressed 
this question. No mortality difference was observed but RRT was avoided 
in 17-37% of the late starters. Moreover, in the most recent trial protocol-
driven classical indications were achieved in only one third of the patients 
in the “late” group; in the other two thirds perceived fluid overload and/or 
oligoanuria was the main indication for RRT 5. Observational trials with 
high risk of residual confounders show conflicting results with one study 
demonstrating improvement only when RRT is commenced when classical 
indications are present 6, whereas others observe a higher mortality in 
patients exhibiting the classical indications on starting RRT, especially 
when RRT is delayed 7,8. Several observational studies used 
retrospective definitions of early and late (based on urea, creatinine, time 
in ICU, AKI stage, time since AKI stage 3 or degree of fluid overload) 
which do not inform as to the reason for starting RRT. Mostly a beneficial 
effect of early start is demonstrated 9. However, there is a high risk of 
bias in these studies as none included a control group without RRT and 
many patients (especially those in the early group) may have received 
unnecessary RRT. A few recent trials did include a control group without 
RRT and showed that, even after propensity score matching, the use of 
RRT increased mortality, especially in less severe forms of AKI 10-11. It 
is evident that this study design also has a high risk of residual 
confounding. Vaara showed lower mortality with pre-emptive RRT in 
propensity matched analysis but a considerable proportion of patients 
could not be matched 8. 
3. Is sepsis an indication to start RRT earlier? Given that RRT is theoretically 
capable of clearing inflammatory mediators several authors consider the 
presence of sepsis as an indication for early RRT. However, this is not 
substantiated by clinical data. A randomized trial comparing early CVVH 
versus standard medical treatment in severe sepsis did actually describe 
worse outcome in the CVVH group with increased number and severity of 
organ failures 12  
4. Does RRT help the holistic management of our patients (concept of organ 
support therapy)? Or does withholding RRT impede us in providing 
adequate therapy e.g. parenteral nutrition, drugs/antibiotics given potential 
problems with volume overload complicating AKI? In clinical practice 
diuretic-resistant oliguria with (established or presumed poorly tolerated) 
fluid overload and/or large obligatory fluid input is a frequent indication 
for RRT 2. Whereas the association between fluid overload and outcome 
is undoubted, the causative link between both remains to be established. 
Indeed, a prospective trial on prevention or reversal of fluid overload with 
early RRT does not exist and it remains even doubtful whether fluid 
mobilization in the early phase of critical illness is at all feasible. 
However, in certain subgroups of patients manipulation of fluid balance to 
prevent fluid overload appears beneficial (stable ARDS, congestive heart 
failure) 13. Besides an assessment of the reversibility of kidney 
dysfunction, the tolerance to fluid overload (mainly cardiac and respiratory 
acute illness and comorbidity) may therefore become an important factor 
in the decision to start RRT. 
5. It is evident that RRT should not be started if the probability of 
spontaneous recovery is high. Unfortunately our ability to predict need for 
RRT in the early stages of AKI is poor although response to loop diuretics 
may perform better than biomarkers 14. In clinical practice trends in 
kidney function and non-renal factors such as severity and potential for 
short-term reversibility of the underlying disease (e.g. nephrotoxic drugs, 
low cardiac output due to hypovolemia versus cardiac failure or septic 
shock) can be very helpful.  
6. In the absence of hard data the decision whether or not to start RRT should 
weigh the harm of unnecessary treatment against the harm of late 
treatment in the patients that will need RRT. “First do not harm”. The 
demonstration that AKI is an independent predictor of mortality has 
fostered the paradigm that earlier initiation of RRT might influence 
outcome. AKI indeed has many systemic consequences 15. However, 
our current RRT modalities can only correct some them, i.e. electrolyte 
and acid base disturbance, fluid overload and uremia. In addition, doubling 
the RRT dose has not been shown to improve outcome and unnecessary 
RRT is not without harm. RRT (especially intermittent hemodialysis) may 
cause hypotension that in turn may delay recovery 16. RRT can result in 
loss of essential substances (nutrients, drugs…), electrolyte imbalance 
with potential for arrhythmias, anticoagulation-related bleeding, 
disequilibrium syndrome, infectious or mechanical complications of the 
dialysis catheter, bio-incompatibility issues, hypothermia, errors in fluid 
balance and last but not least costs 17.  
7. It is evident that RRT should not be started when further treatment is 
considered futile 1.  
 
Premorbidly, our patient was fit and well. Thus starting RRT is appropriate 
especially as the surgery was potentially curative. He did not present with 
classical indications and, although oliguric, had normal oxygenation. He has 
been treated until recently with drugs that potentially impair renal function 
(NSAIDS, ACEI) and his AKI may be at least partially fluid-responsive (history of 
ileus and vomiting). RRT was not started. His creatinine further increased to 5.2 
on the next day but thereafter decreased steadily. 
 
In conclusion, hard evidence to guide the optimal timing to start RRT in patients 
with AKI is lacking resulting in a wide variation in clinical practice. The decision 
to start RRT should be individualized taking into account not only the severity of 
AKI and the trend in kidney function but the also the severity and reversibility of 
the underlying disease, the risk/tolerance of fluid overload and, importantly, the 
potential harm associated with unnecessary RRT (Table). We can only hope that 
the two ongoing RCT’s NCT0168259, NCT01932190, with results expected in 
2016, will provide more answers to this clinical dilemma.  
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Table. Absolute and relative indications for commencing or not commencing RRT. 
 
 
Reasons to start Reasons not to start 
Absolute  Absolute 
Severe hyperkalemia Futile therapy 
Severe acidosis  
Organ dysfunction due to diuretic-
resistant fluid overload 
 
Uremic complications (pericarditis, 
encephalopathy, …) 
 
Life threatening intoxications with 
substances which can be dialysed (low 
protein binding (<50%), low volume 
of distribution and low molecular 
weight)   
 
  
Relative  Relative 
Diuretic-resistant fluid overload Oliguria without clinically important fluid 
overload  
Limited tolerance to fluid overload Sufficient cardiocirculatory and 
respiratory reserve to tolerate fluid 
overload 
Rapidly worsening kidney function Slow deterioration in kidney function 
Underlying disease not rapidly 
reversible 
Potential for short term reversibility of the 
underlying disease 
Reduced risk of harm from RRT  
 
Potential harm of RRT (may include 
unavailability of CRRT) 
Furosemide stress test with UO 2h < 
200ml 
Furosemide stress test with UO 2h 
>200ml 
 
 
 
 
